According to a new report published by Allied Market Research, titled,Europe Early Toxicity Testing Market by Technique, Application and End User: Opportunity Analysis and Industry Forecast, 2018 – 2025,”the Europe early toxicity testing market is expected to reach $460 million by 2025, registering a CAGR of 7.1% from 2018 to 2025, in terms of value.

Download PDF Boucher:

Early toxicity testing is the analysis of a new drug compound in the drug development process. The testing is conducted to determine the damage caused to the body by the compound. Toxicity testing of drugs is vital as it helps in avoiding severe adverse drug reactions in the body. The testing is carried out in different mediums such as in vivo, in vitro, and in silico. These tests are carried out before pre-clinical trials to analyze the drug candidates, which are further tested in clinical studies carried out in humans. Moreover, early toxicology testing is necessary as it can prevent financial losses that occur during the failure of drugs in further late stages of drug development.

Factors that drive the growth of the Europe early toxicity testing market include rise in R&D activities and surge in stringent regulatory authorities concerning public healthcare welfare. In addition, increase in adoption of in vitro model due to strict guidelines in favor of animal protection also serves as factors for the growth of market. However, challenges of preclinical testing hamper the market growth. Furthermore, technological advancements in preclinical procedures provide lucrative opportunities for the market growth. 

Purchase Inquiry:

On the basis of technique, in vitro segment is major revenue contributor in 2017 and is expected to maintain its dominant position throughout the analysis period due to rise in adoption of this technique across different diagnostic areas. Europe is extensively active toward protection of animals. Europe government has banned testing of cosmetic and household products on animals. Therefore, in vitro testing serves as a feasible alternative to in vivo testing, which serves as another major reason for the growth of the in vitro market. Moreover, lower costs associated with carrying out this technique also boost the growth of this market. In silico segment is the fastest growing segment during the forecast period, owing to rise in its adoption due to advantages offered by the technique. In silico techniques have revolutionized the drug discovery process as these techniques are not only applied to find new targets and new molecule with high affinity to those targets but also used to determine the metabolic pathways of those active molecules. In addition, these techniques are computer-based that eliminate animal sacrifice, which is another factor that fuels the growth of this market.

In 2017, Germany accounted approximately one fifth share of the total Europe early toxicity testing market and is expected to continue this trend owing to higher number of R&D activities, high presence of research lab, companies and institutes, and wide availability of technologically advanced preclinical diagnostic instruments. On the other side the UK is estimated to register the fastest growth during the forecast period. 

Key Findings of the Europe Early Toxicity Testing Market:
  • Germany occupied approximately one fifth share of the Europe early toxicity testing market in 2017.
  • The in silico segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • The pharmaceutical industry segment accounted for more than two third share of the market in 2017. 
  • The cosmetic industry is anticipated to grow at the highest rate during the analysis period.

The major companies profiled in this report include Agilent Technologies, Inc., General Electric Company (GE Healthcare), Danaher Corporation (Beckman Coulter, Inc.), Evotec AG (Cyprotex), Bioanalytical Systems, Inc., Bruker Corporation, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.), The Jackson Laboratory. 

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Contact Us:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975

Leave a comment

Your email address will not be published. Required fields are marked *